Results 131 to 140 of about 232,372 (262)

Rare Secondary Neoplasms Arising in Epidermal Nevus: A Case Series and Literature Review

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Malignant transformation is known to occur with many nevi, such as nevus sebaceus. However, cases of secondary tumors developing in an epidermal nevus (EN) are rare, with only a few case reports documented in the literature. We present three unique cases of syringocystadenoma papilliferum (SCAP), syringofibroadenoma, trichilemmoma, and basal ...
Haya A. Homsi   +5 more
wiley   +1 more source

Multicentric Asynchronous Endocrine Mucin‐Producing Sweat Gland Carcinoma and Mucinous Carcinoma of the Skin

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Endocrine mucin‐producing sweat gland carcinoma (EMPSGC) is an adnexal neoplasm which typically occurs on periorbital skin and demonstrates overlapping histopathologic features with primary mucinous carcinoma of the skin (MCS). Herein, we report a patient who developed five distinct lesions of EMPSGC and MCS over an eight‐year period, some of ...
Ikuko Hirai   +5 more
wiley   +1 more source

Discoid Lupus Erythematosus in Genital Skin: A Case Report and Review of the Literature

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Discoid lupus erythematosus (DLE) represents the most common variant of chronic cutaneous lupus erythematosus, a skin‐specific autoimmune disorder within the broader lupus erythematosus spectrum Clinically, DLE is characterized by erythematous, scaly plaques with areas of hyperpigmentation.
Ala' Abu‐Dayeh   +2 more
wiley   +1 more source

Clinical characteristics and follow‐up of 77 patients with pathogenic fumarate hydratase variants

open access: yes
BJU International, EarlyView.
Matthijs Duijn   +12 more
wiley   +1 more source

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Anti‐PD‐1 response has been associated with higher PD‐1 ligand (PD‐L1) expression levels in different cancer types. Cemiplimab, an anti‐PD‐1 antibody, has been shown to induce a response rate of 31% and 22% in patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC respectively, who have progressed or are ...
Isabella Dommann   +9 more
wiley   +1 more source

Uterine papillary serous carcinoma [PDF]

open access: yesOrvosi Hetilap, 2011
Zoltán, Langmár   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy